SDRIFE‐like rash associated with COVID‐19, clinicopathological correlation

Chicharro, Pablo; Rodríguez‐Jiménez, Pedro; Muñoz‐Aceituno, Ester; Argila, D. de; Muñoz‐Hernández, Patricia; Llamas‐Velasco, M.

doi:10.1111/ajd.13444

Cited by 23 publications

(19 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rashes were described as erythematous, millimetric, coalescing macules predominantly distributed at flexural areas. 20,68 Although SDRIFE is classically associated with drug reactions, the rashes reported in these 2 cases may have been associated with COVID-19, as no culprit drug was identified in either patient.…”

Section: Capsule Summary Dmentioning

confidence: 97%

Skin manifestations of COVID-19: A worldwide review

Tan¹,

Tam²,

Oh³

2021

JAAD International

120

144

View full text Add to dashboard Cite

Introduction Because of the increasing emergence of skin manifestations of the coronavirus disease 2019 (COVID-19) worldwide, we investigated the published reports of these lesions. Methods We conducted a literature search for original and review articles published from November 11, 2019, to September 30, 2020. Results We determined five skin lesions common in patients with COVID-19: pseudo-chilblains, maculopapular, urticarial, vesicular, and vaso-occlusive lesions. These lesions manifest at various times in relation to COVID-19 symptoms, which may indicate whether the lesions are virus-induced or are delayed immunological responses to the infection. Skin lesions are more prevalent among Europeans and US residents than among Asians, as is pseudo-chilblain, and the morphology of the skin lesions varies between continents. Pseudo-chilblains are the most common COVID-19 skin manifestation in Europe and the United States, but there is only one reported case from Asian populations. Additionally, patients with vaso-occlusive lesions are more likely than those with pseudo-chilblains to be admitted to the intensive care unit and to die. Conclusion Different cutaneous manifestations in patients with COVID-19 could reflect a wide spectrum of viral interactions with the skin, though reporting bias may play a role as well.

show abstract

Section: Capsule Summary Dmentioning

confidence: 97%

Skin manifestations of COVID-19: A worldwide review

Tan¹,

Tam²,

Oh³

2021

JAAD International

120

144

View full text Add to dashboard Cite

show abstract

“…However, it has not been clearly revealed whether it is related to the drugs used to treat COVID-19 or to COVID-19 infection itself. 8,9 In this case report, we are presenting a case of SDRIFE-like eruption due to COVID-19 vaccine. On the other hand, we could not fully understand the culprit allergen that causes the eruption.…”

Section: Systemic Drug-related Intertriginous and Flexural Exanthema Like Eruption After Coronavac Vaccinementioning

confidence: 99%

Systemic drug‐related intertriginous and flexural exanthema like eruption after CoronaVac vaccine

Orenay

Balta

Yigit

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

“…We have evaluated 20 case reports including 25 cases of COVID‐19 who were treated with multiple drugs in Table 1 4‐23 . In Tables 2, 4 cohort studies are shown.…”

Section: Resultsmentioning

confidence: 99%

A systematic review on treatment‐related mucocutaneous reactions in COVID ‐19 patients

Nobari

Seirafianpour

Mashayekhi

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Most of drugs could have certain mucocutaneous reactions and COVID‐19 drugs are not an exception that we focused. We systematically reviewed databases until August 15, 2020 and among initial 851 articles, 30 articles entered this study (20 case reports, 4 cohorts, and 6 controlled clinical trials). The types of reactions included AGEP, morbiliform drug eruptions, vasculitis, DRESS syndrome, urticarial vasculitis, and so on. The treatments have been used before side effects occur, included: antimalarial, anti‐viral, antibiotics, tocilizumab, enoxaparin and and so on. In pandemic, we found 0.004% to 4.15% of definite drug‐induced mucocutaneous reactions. The interval between drug usage and the eruption varied about few hours to 1 month; tightly dependent to the type of drug and hydroxychloroqine seems to be the drug with highest mean interval. Antivirals, antimalarials, azithromycin, and tocilizumab are most responsive drugs for adverse drug reactions, but antivirals especially in combination with antimalarial drugs are in the first step. Types of skin reactions are usually morbilliform/exanthematous maculopapular rashes or urticarial eruptions, which mostly may manage by steroids during few days. In the setting of HCQ, specific reactions like AGEP should be considered. Lopinavir/ritonavir is the most prevalent used drug among antivirals with the highest skin adverse reaction; ribarivin and remdisivir also could induce cutaneous drug reactions but favipiravir has no or less adverse effects. Logically the rate of dermatologic adverse effects among anivirals may relate to their frequency of usage. Rarely, potentially life‐threatening reactions may occur. Better management strategies could achieve by knowing more about drug‐induced mucocutaneous presentations of COVID‐19.

show abstract

SDRIFE‐like rash associated with COVID‐19, clinicopathological correlation

Cited by 23 publications

References 4 publications

Skin manifestations of COVID-19: A worldwide review

Skin manifestations of COVID-19: A worldwide review

Systemic drug‐related intertriginous and flexural exanthema like eruption after CoronaVac vaccine

A systematic review on treatment‐related mucocutaneous reactions in COVID ‐19 patients

Contact Info

Product

Resources

About